January 3, 2020 NEFLAMAPIMOD in Patients with Lewy Body Dementia Center: Brain Health, Movement Disorders Condition: Dementia Status:Closed A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of the Oral P38 Alpha Kinase Inhibitor Neflamapimod in Dementia with Lewy Bodies (DLB).